Linda Patrick-Miller

Summary

Affiliation: New Jersey
Country: USA

Publications

  1. pmc Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy
    Robert S DiPaola
    Department of Medicine, University of Medicine and Dentistry of New Jersey UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Prostate 68:1743-52. 2008
  2. ncbi Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:6-13. 2005
  3. ncbi Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer
    Susan Goodin
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Piscataway, USA
    J Clin Oncol 23:3352-7. 2005
  4. pmc Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
    Mark Stein
    The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick, NJ 08901, USA
    Med Sci Monit 18:CR260-4. 2012
  5. pmc Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials
    Wenfeng Kang
    Department of Radiation Oncology and Center for Systems Biology, The Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA
    BMC Med Res Methodol 13:77. 2013
  6. pmc A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer
    R S DiPaola
    The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    J Transl Med 4:1. 2006
  7. ncbi Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer
    Robert S DiPaola
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08901, USA
    J Clin Oncol 20:1874-9. 2002
  8. pmc A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
    Robert S DiPaola
    Department of Medicine, The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick NJ, USA
    J Transl Med 8:20. 2010
  9. ncbi National cooperative group trials
    Robert S DiPaola
    Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
    Urology 65:23-9; discussion 29. 2005
  10. ncbi Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma
    R S DiPaola
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Cancer 92:2065-71. 2001

Detail Information

Publications52

  1. pmc Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy
    Robert S DiPaola
    Department of Medicine, University of Medicine and Dentistry of New Jersey UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Prostate 68:1743-52. 2008
    ..The understanding of autophagy, as either a mechanism of resistance to therapies that induce metabolic stress, or as a means to cell death, is rapidly expanding and supportive of a new paradigm of therapeutic starvation...
  2. ncbi Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:6-13. 2005
    ..These data support the dose selection of ongoing phase 2 studies of G3139 at 7 mg/kg/d and docetaxel 75 mg/m2...
  3. ncbi Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer
    Susan Goodin
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Piscataway, USA
    J Clin Oncol 23:3352-7. 2005
    ..To evaluate docetaxel in the treatment of patients with early-stage prostate cancer with prostate-specific antigen (PSA) progression after local therapy without androgen ablation therapy...
  4. pmc Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
    Mark Stein
    The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick, NJ 08901, USA
    Med Sci Monit 18:CR260-4. 2012
    ....
  5. pmc Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials
    Wenfeng Kang
    Department of Radiation Oncology and Center for Systems Biology, The Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA
    BMC Med Res Methodol 13:77. 2013
    ..In some instances these interactions can be anticipated based on pre-clinical models. However, the anticipation of drug interactions in the clinical context is in general a challenging task...
  6. pmc A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer
    R S DiPaola
    The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    J Transl Med 4:1. 2006
    ....
  7. ncbi Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer
    Robert S DiPaola
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08901, USA
    J Clin Oncol 20:1874-9. 2002
    ....
  8. pmc A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
    Robert S DiPaola
    Department of Medicine, The Cancer Institute of New Jersey, UMDNJ RWJMS, New Brunswick NJ, USA
    J Transl Med 8:20. 2010
    ....
  9. ncbi National cooperative group trials
    Robert S DiPaola
    Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
    Urology 65:23-9; discussion 29. 2005
    ..This article reviews the national cooperative group clinical trials, whether currently open or planned, and suggests practical strategies to improve accrual...
  10. ncbi Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma
    R S DiPaola
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Cancer 92:2065-71. 2001
    ..Therefore, the authors hypothesized that chemotherapy in patients with prostate specific antigen (PSA) progression after local therapy, before androgen ablation therapy, will have greater antitumor activity...
  11. ncbi Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies
    R S DiPaola
    Departments of Medicine and Pharmacology, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, USA
    J Clin Oncol 17:2213-8. 1999
    ..Pharmacodynamic studies were performed to determine whether CRA and IFNalpha could modulate bcl-2 expression in vitro and in patients...
  12. ncbi State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey
    R S DiPaola
    Department of Medicine, Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, USA
    N J Med 98:23-33. 2001
    ..This review summarizes the recent efforts in diet, screening, novel systemic therapies, and alternative medicine for prostate cancer...
  13. ncbi Furanosesquiterpenoids of Commiphora myrrha
    N Zhu
    Department of Food Science, Rutgers University, New Brunswick, New Jersey 08901, USA
    J Nat Prod 64:1460-2. 2001
    ..Compound 1 exhibited weak cytotoxic activity against a MCF-7 breast tumor cell line in a clonogenic assay, while the other five compounds were inactive in this assay...
  14. ncbi Targeting apoptosis in prostate cancer
    R S DiPaola
    Dean and Betty Gallo Prostate Cancer Center, New Brunswick, New Jersey, USA
    Hematol Oncol Clin North Am 15:509-24. 2001
    ..The continued study of new targets, agents capable of modulating these targets, and markers of biologic effect in patients should improve clinical results...
  15. ncbi A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Susan Goodin
    Department of Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    Cancer Chemother Pharmacol 56:199-204. 2005
    ..The combination of docetaxel and vinorelbine with filgrastim was well tolerated and active against HRPC in patients with or without prior chemotherapy...
  16. ncbi Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma
    Roger K Strair
    Division of Medical Oncology and Surgical Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    J Clin Oncol 21:3785-91. 2003
    ..The cells are irradiated to prevent graft-versus-host disease...
  17. ncbi Clinical and biological activity of soy protein powder supplementation in healthy male volunteers
    Susan Goodin
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08903 2681, USA
    Cancer Epidemiol Biomarkers Prev 16:829-33. 2007
    ....
  18. ncbi A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies
    A Thalasila
    The Dean and Betty Gallo Prostate Cancer Center at The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Cancer Chemother Pharmacol 52:119-24. 2003
    ..To develop a marker of drug effect, we assessed bcl-2 downregulation in patient peripheral blood mononuclear cells (PBMC)...
  19. pmc Outcomes of localized prostate cancer following conservative management
    Grace L Lu-Yao
    Cancer Institute of New Jersey, and Department of Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, USA
    JAMA 302:1202-9. 2009
    ..Although conservative management can be a reasonable choice, there is little contemporary prostate-specific antigen (PSA)-era data on outcomes with this approach...
  20. doi Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies
    Mark Stein
    Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08901, USA
    Prostate 70:1388-94. 2010
    ....
  21. doi A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer
    Mecide Gharibo
    The Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA
    Pancreas 36:341-5. 2008
    ..The aim of the study was to assess the clinical efficacy and toxicity of single-agent imatinib mesylate in patients with advanced, unresectable metastatic pancreatic cancer...
  22. ncbi Bioactive constituents from gum guggul (Commiphora wightii)
    N Zhu
    Department of Food Science and Center for Advanced Food Technology, Rutgers University, New Brunswick, NJ 08901, USA
    Phytochemistry 56:723-7. 2001
    ..This fraction also showed moderate scavenging effect against 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals...
  23. pmc Bcl-2 modulation to activate apoptosis in prostate cancer
    Kevin Bray
    The Cancer Institute of New Jersey, New Brunswick, NJ 08903 2681, USA
    Mol Cancer Res 7:1487-96. 2009
    ..Thus, rational targeting of both the Bcl-2 and Mcl-1 mechanisms of apoptosis resistance may be therapeutically advantageous for advanced prostate cancer...
  24. pmc Contemporary risk profile of prostate cancer in the United States
    Yu Hsuan Shao
    Department of Population Science, Cancer Institute of New Jersey, New Brunswick, NJ, USA
    J Natl Cancer Inst 101:1280-3. 2009
    ..In conclusion, more men were diagnosed with prostate cancer at a younger age and earlier stage in 2004-2005 than in earlier years. The racial disparity in cancer stage at diagnosis has decreased statistically significantly over time...
  25. ncbi Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies
    Robert S DiPaola
    Department of Medicine, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    Med Sci Monit 9:PI5-11. 2003
    ..To investigate a novel schedule of gemcitabine (G), paclitaxel (P), and carboplatin (C), based on preclinical studies demonstrating greater activity and decreased toxicity of administering P prior to C...
  26. ncbi An evidence-based approach to prostate cancer follow-up
    Siu Long Yao
    Cancer Institute of New Jersey, The Dean and Betty Gallo Prostate Cancer Center, New Brunswick, NJ 08901, USA
    Semin Oncol 30:390-400. 2003
    ..Finally, follow-up as a means to determine eligibility for clinical studies is discussed...
  27. ncbi Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:679-83. 2002
    ..To evaluate the safety and pharmacokinetics of BCL-2 antisense oligonucleotide (G3139) administered by prolonged i.v. infusion in patients with advanced cancer...
  28. ncbi A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer
    Kamakshi Rao
    The Dean and Betty Gallo Prostate Cancer Center at The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Prostate 62:115-22. 2005
    ....
  29. pmc Survival following primary androgen deprivation therapy among men with localized prostate cancer
    Grace L Lu-Yao
    Department of Environmental and Occupational Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    JAMA 300:173-81. 2008
    ..Despite a lack of data, increasing numbers of patients are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management for the treatment of localized prostate cancer...
  30. ncbi Population based study of hormonal therapy and survival in men with metastatic prostate cancer
    Grace Lu-Yao
    Department of Environmental and Occupational Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    J Urol 177:535-9. 2007
    ....
  31. ncbi Use of hormonal therapy in men with metastatic prostate cancer
    Grace Lu-Yao
    Department of Environmental and Occupational Medicine, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    J Urol 176:526-31. 2006
    ..In this population based study we assessed the use rates of these therapies in men who died of prostate cancer...
  32. ncbi To arrest or not to G(2)-M Cell-cycle arrest : commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. cancer res., 8: 3512-3519, 2
    Robert S DiPaola
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901, USA
    Clin Cancer Res 8:3311-4. 2002
  33. ncbi A novel proteomic coculture model of prostate cancer cell growth
    Dmitri Dvorzhinski
    The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
    Proteomics 4:3268-75. 2004
    ..These data, therefore, demonstrate a novel coculture model for further study of agents that target proteins in pathways of paracrine or autocrine stimulated cell growth...
  34. ncbi Metastatic renal cell carcinoma presenting as an oral tumor
    M K Ankem
    Division of Urology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903-0019, USA
    Can J Urol 8:1295-6. 2001
    ..Metastatic cancer presenting as an oral lesion is exceedingly uncommon. To the best of our knowledge this is the first reported instance of renal cell carcinoma presenting initially as an oral lesion...
  35. ncbi A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation
    Mohamed M Rafi
    Department of Food Science, New Jersey Agricultural Experimentation Station, Cook College, Rutgers University, New Brunswick, New Jersey 08901 8520, USA
    Anticancer Res 25:313-8. 2005
    ..Although initially active in clinical studies, current anti-microtubule agents are only temporarily effective and the discovery of new agents is warranted...
  36. ncbi Epothilone induced cytotoxicity is dependent on p53 status in prostate cells
    Margarita L Ioffe
    The Cancer Institute of New Jersey, Robert Wood Johnson Medical School UMDNJ, New Brunswick, New Jersey 08901, USA
    Prostate 61:243-7. 2004
    ..We hypothesized that epothilone induced cytotoxicity would be influenced by the status of p53 in prostate cells...
  37. ncbi State-of-the-art treatment of metastatic hormone-refractory prostate cancer
    Susan Goodin
    The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
    Oncologist 7:360-70. 2002
    ..Evaluation and incorporation of these agents into existing treatment regimens will guide us in the development of more active regimens in the treatment of HRPC...
  38. ncbi Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice
    Whitney Banach-Petrosky
    The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, USA
    Clin Cancer Res 12:5895-901. 2006
    ..1; Pten mutant mice, which recapitulate stages of prostate carcinogenesis from prostate intraepithelial neoplasia (PIN) to adenocarcinoma...
  39. pmc Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml
    Yu Hsuan Shao
    Dean and Betty Gallo Prostate Cancer Center, Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, USA
    Arch Intern Med 170:1256-61. 2010
    ..Despite controversy over the benefit of prostate-specific antigen (PSA) screening, little is known about risk profiles and treatment patterns in men diagnosed as having prostate cancer who have a PSA value less than or equal to 4.0 ng/mL...
  40. ncbi Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines
    Mohamed M Rafi
    Department of Food Science and Center for Advanced Food Technology, Rutgers University, 65 Dudley Road, New Brunswick, New Jersey 08901 8520, USA
    J Agric Food Chem 50:677-84. 2002
    ....
  41. ncbi A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
    Eric J Small
    University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    BJU Int 100:765-9. 2007
    ....
  42. ncbi Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
    Adam S Kibel
    Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63105, USA
    J Urol 177:1777-81. 2007
    ..Patients with adverse pathological features are at high risk for recurrence following radical prostatectomy. To improve outcomes in this population we performed a phase II study of adjuvant docetaxel in these high risk patients...
  43. ncbi Pox viral vaccine approaches
    Philip M Arlen
    Laboratory of Tumor Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 32:549-55. 2005
    ....
  44. ncbi Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate
    Parvesh Kumar
    Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, 90033 0804, USA
    J Clin Oncol 22:1909-15. 2004
    ..A phase I trial was conducted to determine the maximally tolerated dose (MTD) of concurrent weekly docetaxel and three-dimensional conformal radiation therapy (3-D CRT) in unfavorable localized adenocarcinoma of the prostate...
  45. ncbi PC-SPES: herbal formulation for prostate cancer
    Leonard S Marks
    Urological Sciences Research Foundation, Culver City, California 90232, USA
    Urology 60:369-75; discussion 376-7. 2002
    ..PC-SPES is of great interest in men with androgen-independent CaP, an area in which future research should be primarily directed...
  46. doi Hearsay medicine is not evidence-based medicine
    Robert S DiPaola
    Clin Cancer Res 14:337-8. 2008
  47. ncbi Bone directed therapies for prostate cancer
    Deborah A Bradley
    Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Urol 178:S42-8. 2007
    ..We provide an overview of recent advances in understanding bone biology, and bone targeted therapy research and development...
  48. ncbi Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference
    Philip W Kantoff
    Lank Center for Genitourinary Oncology, Boston, Massachusetts, USA
    J Urol 178:S5-8; quiz S4. 2007
  49. ncbi High time for low-dose prospective clinical trials
    Robert S DiPaola
    Cancer 98:1559-61. 2003
  50. ncbi Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 22:3705-12. 2004
    ..To evaluate the herbal combination, PC-SPES, and diethylstilbestrol (DES) in patients with androgen independent prostate cancer (AIPC)...
  51. ncbi Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group
    Howard L Kaufman
    Columbia University Medical Center, 177 Fort Washington Avenue, New York, NY 10032, USA
    J Clin Oncol 22:2122-32. 2004
    ..The induction of PSA-specific immunity was also evaluated...
  52. ncbi Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy
    Robert S DiPaola
    J Urol 178:1840-1. 2007